SFPG
MRNA icon

Stonebridge Financial Planning Group’s Moderna MRNA Stock Holding History

Stonebridge Financial Planning Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,340
Closed -$241K – 127
2022
Q4 		$241K Buy
+1,340
New +$219K 0.16% 111
2022
Q2 		– Sell
-1,360
Closed -$234K – 120
2022
Q1 		$234K Sell
1,360
-350
-20% -$58.9K 0.13% 104
2021
Q4 		$273K Sell
1,710
-50
-3% -$14.6K 0.14% 103
2021
Q3 		$609K Sell
1,760
-125
-7% -$46.1K 0.3% 70
2021
Q2 		$451K Buy
1,885
+20
+1% +$3.57K 0.24% 76
2021
Q1 		$260K Hold
1,865
– – 0.15% 94
2020
Q4 		$195K Buy
1,865
+200
+12% +$20.2K 0.12% 104
2020
Q3 		$123K Buy
1,665
+1,265
+316% +$88.2K 0.09% 119
2020
Q2 		$23K Buy
400
+100
+33% +$5.48K 0.02% 247
2020
Q1 		$10K Buy
+300
New +$6.9K 0.01% 302

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Stonebridge Financial Planning Group's MRNA Position: Q1 2023 in Review

Stonebridge Financial Planning Group sold out of Moderna (MRNA) in Q1 2023, closing a stake of 1,340 shares — an estimated $241K sold.

Stonebridge Financial Planning Group first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $609K in Q3 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Stonebridge Financial Planning Group reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Stonebridge Financial Planning Group sold 1,340 Moderna shares in Q1 2023, an estimated $241K.
  • Stonebridge Financial Planning Group first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
  • Stonebridge Financial Planning Group's Moderna position peaked at $609K in Q3 2021.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Stonebridge Financial Planning Group's 13F filing for Q1 2023, filed 4 May 2023.